Design, Characterization and Molecular Docking Study of the New Isoxazolidine-1,2,3-Triazole Hybrids

Abstract

Polycyclics are considered among the most widely used compounds in drug discovery. Isoxzolidine-triazole hybrids have multiple medicinal properties, including anti-inflammatory and anti-tumor agents. In this work, we synthesized a new series of isoxazolidine-triazole hybrids and study molecular docking of the synthesized compounds to determine the binding interactions with target protein PIKα (PDB ID: 3ZIM). With a docking score of -10.4 kcal/mol, 7e demonstrated good binding affinity to the active site of PI3K among all synthesized compounds.